Research use only · Not for human or veterinary useFor laboratory research use only. Not a medicine. Not for human or veterinary use.
Rierink Compounds
EU — Research use only
Confirm before entering the catalog
By continuing, you confirm you are 18 or older and that all materials are acquired strictly for laboratory research. Not a medicine. Not for human or veterinary use.
Leave this siteBlog
Notes on published findings, new compounds, and how to read the documents we keep. Briefings are not medical advice and do not include protocols.
Sign in to accept email when a blog post is published or a catalog quantity is updated on the shelf.
Sign in
2 November 2026
The open-catalog entry for survodutide describes a synthetic acylated 29-amino-acid peptide dual agonist of glucagon and GLP-1 receptors supplied as high-purity lyophilized powder for laboratory metabolic research. Randomised trials report
Read briefing
1 November 2026
Dulaglutide is a recombinant Fc-fusion GLP-1 receptor agonist engineered for once-weekly administration in laboratory and clinical metabolic research. Randomised trials report glycaemic improvements, cardiovascular risk reduction and modest
Read briefing
31 October 2026
The open-catalog cagrilintide-semaglutide mixture supplies a research pairing of an amylin receptor agonist and GLP-1 receptor agonist for laboratory metabolic studies. Randomised trials of co-administration report enhanced weight loss (13–
Read briefing
31 October 2026
The catalog lists Pinealon at /compounds/pinealon as the single synthetic tripeptide Glu-Asp-Arg (EDR), a chemically defined research compound supplied as one discrete molecular entity distinct from tissue extracts or peptide mixtures, with
Read briefing
31 October 2026
Liraglutide is a synthetic 31-amino-acid lipopeptide analogue of human GLP-1(7-37) with an Arg34 substitution and Lys26 acylated by palmitic acid via a γ-glutamic acid spacer (C172H265N43O51, CAS 204656-20-2). It is tracked as a single disc
Read briefing
30 October 2026
Published reports and pharmacopeial standards characterize BAC water as sterile Water for Injection containing 0.9% benzyl alcohol as bacteriostatic preservative, serving as a common laboratory reagent for reconstituting research peptides i
Read briefing
30 October 2026
Published reports characterize Melanotan II as a synthetic cyclic heptapeptide non-selective melanocortin receptor agonist with preclinical data on melanogenesis, appetite suppression and sexual behavior, small early human trials showing ta
Read briefing
30 October 2026
Published reports characterize PT-141 (bremelanotide) as a synthetic cyclic heptapeptide melanocortin receptor agonist with foundational preclinical data on central sexual motivation pathways and two phase 3 randomised trials demonstrating
Read briefing
29 October 2026
Published reports characterize VIP (vasoactive intestinal peptide; synthetic form aviptadil) as a 28-amino-acid neuropeptide acting via VPAC1/VPAC2 receptors to mediate vasodilation, bronchodilation, and potent anti-inflammatory/immunomodul
Read briefing
29 October 2026
Published reports characterize oxytocin acetate as the acetate salt of the endogenous nonapeptide hormone with robust randomised trial and Cochrane evidence for intravenous use in labor induction, augmentation, and postpartum hemorrhage pre
Read briefing
29 October 2026
Published reports characterize P21 (P021), a CNTF-derived adamantane-modified tetrapeptide mimetic, as a preclinical tool studied for promotion of hippocampal neurogenesis, BDNF upregulation, synaptic plasticity, reduced tau hyperphosphoryl
Read briefing
29 October 2026
Indexed papers characterize Thymalin as a bovine thymus polypeptide complex studied predominantly in Russian preclinical and clinical reports for immune modulation in aging and infection. Preclinical models report T-cell differentiation and
Read briefing
28 October 2026
Published reports characterize semaglutide as a long-acting GLP-1 receptor agonist with extensive randomised trial data showing 10–15% weight reduction, glycemic improvement, and cardiovascular benefits in adults with obesity or type 2 diab
Read briefing
28 October 2026
Published reports characterize NAD as an essential redox coenzyme and substrate for sirtuins, PARPs and CD38 studied extensively in metabolism, aging and disease models. Preclinical animal studies report metabolic, mitochondrial and neuropr
Read briefing
28 October 2026
Published reports characterize Melanotan I (afamelanotide or [Nle4-D-Phe7]-α-MSH) as a potent synthetic analog of α-melanocyte-stimulating hormone studied for MC1R-mediated eumelanin induction, photoprotection, and dermatologic indications.
Read briefing
28 October 2026
No peer-reviewed studies or registered trials indexed in PubMed, Europe PMC, or ClinicalTrials.gov characterize or test the research peptide sold as Adamax. Independent 2026 evidence reviews confirm zero direct records, with all functional
Read briefing
27 October 2026
No peer-reviewed clinical trials, animal models, or product-specific mechanistic reports on injectable Lemon Bottle exist in PubMed, Europe PMC, or ClinicalTrials.gov. Published literature is limited to regulatory laboratory analyses docume
Read briefing
27 October 2026
Published preclinical reports on Adipotide document rapid weight loss (approximately 11% in primates, up to 30% in rodents) and substantial white adipose tissue reduction via targeted endothelial apoptosis in obese animal models, accompanie
Read briefing
27 October 2026
Indexed papers characterize L-carnitine as a quaternary ammonium compound essential for mitochondrial long-chain fatty acid transport via the carnitine shuttle. Meta-analyses of randomised trials report modest reductions in body weight, BMI
Read briefing27 October 2026
We have opened a public fund that pays for independent laboratory tests of Rierink lots. It is optional, it starts with €126.00 in the pool, and you decide what gets tested next.
Read briefing
27 October 2026
Preclinical studies on GHK-Cu report consistent stimulation of collagen synthesis, anti-inflammatory effects, and accelerated wound healing in cell and animal models. Human topical trials are small and mixed, with favorable signals in selec
Read briefing
26 October 2026
Indexed papers describe melatonin as an endogenous pineal hormone (N-acetyl-5-methoxytryptamine) studied for circadian regulation, MT1/MT2 receptor signaling, antioxidant activity, sleep physiology, and clinical readouts in insomnia, deliri
Read briefing
26 October 2026
Clinical trials and meta-analyses of tirzepatide report substantial mean weight loss (15–21%), glycemic improvements, cardiometabolic benefits, heart failure event reduction, and superior weight loss versus semaglutide. These are accompanie
Read briefing
26 October 2026
Indexed preclinical and clinical papers describe tirzepatide as a dual GIP/GLP-1 receptor agonist studied for glycemic and weight-related readouts. Reports document substantial reductions in HbA1c (up to 2.6%) and body weight (15-21% in key
Read briefing
25 October 2026
Summarize published reports on glutathione as a standalone compound, limited to what those reports state about identity, study context, and reported findings.
Read briefing
25 October 2026
Clinical trials of retatrutide (LY3437943), a GIP/GLP-1/glucagon triple receptor agonist, report substantial mean weight loss (18-25% at 80 weeks in phase 3 TRIUMPH studies), glycemic improvements, cardiometabolic benefits, and gains in knee osteoarthritis pain and obstructive sleep apnea. However, dose-dependent gastrointestinal adverse events, dysesthesia, increased heart rate, and higher discontinuation rates are consistently reported alongside inconclusive cardiovascular outcomes and data gaps on long-term safety.
Read briefing
25 October 2026
Indexed preclinical and clinical papers describe retatrutide (LY3437943) as a unimolecular triple agonist of GIP, GLP-1, and glucagon receptors studied for weight loss, glycemic control, energy expenditure, and cardiometabolic readouts. Pha
Read briefing25 October 2026
Indexed preclinical and clinical papers describe tirzepatide as a dual GIP/GLP-1 receptor agonist studied for glycemic and weight-related readouts, distinct from the single-incretin, GHRH-analog, and mitochondrial-peptide literature already
Read briefing
25 October 2026
Indexed cell and animal papers describe dihexa as a synthetic angiotensin IV analog studied for hepatocyte-growth-factor and synaptogenesis readouts, distinct from the ACTH-fragment, tuftsin-related, and tripeptide nootropic literature alre
Read briefing
24 October 2026
Indexed cell and animal papers describe KPV as a C-terminal alpha-MSH tripeptide studied for melanocortin and inflammatory readouts, distinct from the gastric injury-model, thymic, and cathelicidin peptides already briefed. Those records do
Read briefing
24 October 2026
Indexed cell, animal, and limited human papers describe epithalon as a synthetic tetrapeptide studied for pineal and telomerase-related readouts, distinct from the senescent-cell, mitochondrial, and metabolic peptides already briefed. Recor
Read briefing
24 October 2026
Indexed cell, animal, and limited clinical papers describe Ara-290 as a synthetic innate-repair-receptor peptide studied for small-fiber and inflammatory readouts, distinct from the injury-model and thymic peptides already briefed, and thos
Read briefing
23 October 2026
Indexed cell, animal, and cosmetic-science papers describe GHK-Cu as a copper-binding tripeptide studied for gene-expression and matrix readouts, distinct from the SNARE-targeted cosmetic octapeptide and the injury-model peptides already br
Read briefing
22 October 2026
Indexed cell, animal, and clinical papers describe thymosin alpha-1 as a synthetic thymic peptide studied for immune-cell readouts, and those records do not establish research-vial use.
Read briefing
22 October 2026
Indexed cell, animal, and clinical papers describe SS-31 as a mitochondria-targeting tetrapeptide studied for cardiolipin interaction and organ-function readouts, and those records do not establish research-vial use.
Read briefing22 October 2026
Summarize what cell, animal, and limited human papers report for the synthetic heptapeptide Selank, naming study type and a limitation for each record without use guidance.
Read briefing
22 October 2026
Indexed papers describe DSIP as a short sleep-related peptide studied mainly in older animal and limited human physiological reports, and those records do not establish research-vial use. [DSIP](/compounds/dsip) is for laboratory research o
Read briefing
22 October 2026
Indexed cell and animal papers describe dihexa as a short angiotensin-IV-related peptidomimetic studied for hepatocyte-growth-factor pathway effects in models of cognitive impairment and neurodegeneration, and those records do not establish
Read briefing
22 October 2026
Indexed cell and animal papers describe FOXO4-DRI as a designed D-retro-inverso peptide that interferes with the FOXO4–p53 interaction, and those records do not establish research-vial use.
Read briefing
22 October 2026
Indexed papers describe epithalon as a short synthetic pineal tetrapeptide studied mainly in cell and animal models, and those records do not establish research-vial use.
Read briefing
21 October 2026
Indexed cosmetic and in vitro reports describe SNAP-8 (acetyl octapeptide-3) as a short acetylated peptide studied in topical formulations and delivery systems. This evidence base of in-vitro SNARE assays, nanoparticle carriers, analytical
Read briefing
21 October 2026
Published papers identify cagrilintide as a long-acting amylin-receptor agonist rather than another GLP-1 or dual incretin peptide, and those records do not establish anything about research-vial use. Cagrilintide is for laboratory research
Read briefing
21 October 2026
Indexed papers reported ARA-290 (cibinetide) findings in small clinical neuropathy studies in sarcoidosis and type 2 diabetes patients and in related preclinical models. Each summary states the study type and a limitation. Reporting a human trial is not guidance to use the research material. [ARA-290](/compounds/ara-290) is for laboratory research only.
Read briefing
21 October 2026
Journal papers report 5-Amino-1MQ as an NNMT inhibitor in cells and in mice. No human trial was identified in this briefing; that gap is not evidence of safety.
Read briefing
21 October 2026
A 2025 British Journal of Pharmacology report described Semax in female mice with spinal cord injury and in neuroinflammation models, with computational target predictions. Findings are study reports only.
Read briefing
21 October 2026
Indexed clinical papers on semaglutide, tirzepatide, and retatrutide reported assigned-arm differences in percent body-weight change and recorded adverse events. Each note names the study type and a limitation. No use guidance is included.
Read briefing
21 October 2026
Two 2025 papers reported animal-model measurements after Semax exposure in transgenic Alzheimer mice and in female mice after spinal cord injury. Neither paper is a clinical study.
Read briefing
21 October 2026
Four clinical papers reported body-weight or HbA1c changes with mazdutide versus placebo or dulaglutide, each with stated population and safety limitations.
Read briefing
21 October 2026
A 2025 British Journal of Pharmacology paper reported Semax findings in female mice after spinal cord injury, plus computational target analyses. Human outcomes were not reported.
Read briefing
21 October 2026
Four PubMed-indexed papers from 2025–2026 report animal-model experiments or narrative reviews involving Semax. None of the records summarized here is a clinical study, and two reviews do not present original Semax measurements.
Read briefing
21 October 2026
Indexed 2025 papers reported in vitro findings on LL-37, truncated fragments, and a designed derivative, plus a review of modification strategies. No clinical outcomes were stated in the records used here.
Read briefing
21 October 2026
Briefing on what peer-reviewed papers reported for the tripeptide KPV: in vitro transporter and cytokine readouts, and mouse colitis-model histology. No clinical trial is summarized.
Read briefing
21 October 2026
In vitro, clinical, and review reports on thymosin alpha-1, each with study type and a stated limitation. Observations only; no health claims.
Read briefing
21 October 2026
Two 2026 systematic reviews summarized preclinical and limited human records on GHK-Cu. Both are secondary syntheses, not new experiments.
Read briefing20 October 2026
Continue with Google on the sign-in and registration pages. The same email stays on one account.
Read briefing
20 October 2026
A short researcher note on what two published phase 2 trials reported about retatrutide, with study type and a limitation for each. No use guidance.
Read briefing
19 October 2026
Four published records describe a commentary on a clinical crossover trial and three animal-model papers on elamipretide (SS-31), one of which also included a cell assay.
Read briefing28 September 2026
A map of the metabolic-research peptides currently listed, without a protocol attached.
Read briefing21 September 2026
What a lot certificate can tell a laboratory, and what it deliberately does not prove.
Read briefing